4300 El Camino Real
Los Altos, CA 94022
Full Time Employees: 12
|Dr. Shalabh K. Gupta M.D., MPA||Founder, Chairman, CEO & Pres||1.46M||N/A||1974|
|Dr. Pramod Gupta Ph.D.||Exec. VP of Pharmaceutical & Bus. Operations||779.18k||N/A||1960|
|Mr. Douglas Jermasek M.B.A.||Exec. VP of Corp. Strategy||430.81k||N/A||1961|
|Mr. John W. Townsend CPA||Chief Financial Officer||N/A||N/A||1962|
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.
Unicycive Therapeutics, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.